Privia Health Group: Operating Leverage Could Lead To Share Price Upside

Privia Health Group is rated BUY, supported by strong operating leverage and expanding value-based care, positioning for earnings upside. PRVA trades at a 48% discount to its five-year average forward EV/EBITDA, with 24% forward EBITDA growth, outpacing peers. 2Q26 results showed 15% care margin growth, 29% adjusted EBITDA growth, and robust provider and patient expansion, highlighting operating efficiency.

Seeking Alpha • Oct 22, 2026

Privia Health to Report Third Quarter 2026 Results on Thursday, November 5

ARLINGTON, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third-quarter and nine-month periods ended September 30, 2026 before market open on Thursday, November 5, 2026.

GlobeNewsWire • Oct 8, 2026

Anthem Blue Cross and Blue Shield in Virginia and Privia Health Reach New Agreement

RICHMOND, Va.--(BUSINESS WIRE)--Anthem Blue Cross and Blue Shield in Virginia and Privia Health have reached a new agreement that will continue providing Anthem members with in-network access to Privia Medical Group physicians across Virginia.The agreement reflects a shared commitment to ensuring Virginians have access to high-quality healthcare while advancing value-based care and helping keep healthcare affordable.“Strong partnerships with physicians are essential to improving healthcare for t.

Business Wire • Oct 5, 2026

Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors

ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D.

GlobeNewsWire • Aug 18, 2026

Privia Health Group Q2 Earnings Call Highlights

Privia Health Group NASDAQ: PRVA reported second-quarter results marked by double-digit growth in implemented providers, attributed lives and practice collections, while adjusted EBITDA rose 29% from a year earlier. Management also raised its 2026 outlook for several financial measures following what Chief Executive Officer Parth Mehrotra described as strong first-half execution.

MarketBeat • Aug 7, 2026

Privia Health Group, Inc. (PRVA) Q2 2026 Earnings Call Transcript

Privia Health Group, Inc. (PRVA) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results

2Q'26 Net Income of $9.0M, +236.7% from 2Q'25 2Q'26 Adjusted EBITDA of $37.4M, +29.1% from 2Q'25 Full-Year 2026 Guidance Raised for All Key Financial Metrics ARLINGTON, Va., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the second quarter and six-month periods ended June 30, 2026.

GlobeNewsWire • Aug 6, 2026

Compared to Estimates, Privia Health (PRVA) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Aug 6, 2026

Privia Health (PRVA) Misses Q2 Earnings Estimates

Privia Health (PRVA) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.02 per share a year ago.

Zacks Investment Research • Aug 6, 2026

What Does a Privia Health Insider's Sale of Company Shares for $3.6 Million Mean for Investors?

Former CEO Shawn Morris sold 135,498 shares on June 30 and July 1, 2026, generating proceeds of ~$3.57 million at a weighted average price around $26.32 per share. Morris' sale reduced direct ownership to 76,651 shares post-transaction.

The Motley Fool • Jul 12, 2026